Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081614 | 0.92 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4SCN9ANOS1 | |
| SCHEMBL3477064 | 0.91 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4SCN9ANOS1 | |
| SCHEMBL3476770 | 0.87 | NOS1 (0.42) | SLC6A2SLC6A3SLC6A4SCN9ANOS1 | |
| SCHEMBL3081775 | 0.86 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4L3MBTL1TDO2 | |
| SCHEMBL3087994 | 0.85 | NOS1 (0.40) | SLC6A2SLC6A3SLC6A4SCN9ANOS1 | |
| SCHEMBL3081668 | 0.85 | GSK3B (0.41) | SLC6A2SLC6A3SLC6A4SCN9ATDO2 | |
| SCHEMBL3071510 | 0.84 | SLC6A2 (0.50) | SLC6A2SLC6A3SLC6A4SCN9AOPRM1 | |
| SCHEMBL3475116 | 0.83 | NOS1 (0.42) | SLC6A2SLC6A3SLC6A4SCN9ANOS1 | |
| SCHEMBL3083522 | 0.82 | KMT2A (0.38) | SLC6A2SLC6A3SLC6A4TDO2 | |
| SCHEMBL3084823 | 0.80 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987252-B2 | Aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-03-24 | — | — | US | claimed |
| US-8987252-B2 | Aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20100210624-A1 | ARYLOXY- AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210624-A1 | ARYLOXY- AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ADRA2B, HTR2B, ADRA1B | SLC6A2 10/4885SLC6A3 13/4885SLC6A4 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.